Enhanced nigrostriatal neuron-specific, long-term expression by using neural-specific promoters in combination with targeted gene transfer by modified helper virus-free HSV-1 vector particles by Cao, Haiyan et al.
BioMed  Central
Page 1 of 14
(page number not for citation purposes)
BMC Neuroscience
Open Access Methodology article
Enhanced nigrostriatal neuron-specific, long-term expression by 
using neural-specific promoters in combination with targeted gene 
transfer by modified helper virus-free HSV-1 vector particles
Haiyan Cao, Guo-rong Zhang, Xiaodan Wang, Lingxin Kong and 
Alfred I Geller*
Address: Department of Neurology, West Roxbury VA Hospital/Harvard Medical School, W. Roxbury, MA 02132, USA
Email: Haiyan Cao - haiyan_cao@hms.harvard.edu; Guo-rong Zhang - guorong_zhang@hms.harvard.edu; 
Xiaodan Wang - xiaodan_wang@hotmail.com; Lingxin Kong - lxkong@ureach.com; Alfred I Geller* - alfred_geller@hms.harvard.edu
* Corresponding author    
Abstract
Background: Direct gene transfer into neurons has potential for developing gene therapy treatments for
specific neurological conditions, and for elucidating neuronal physiology. Due to the complex cellular
composition of specific brain areas, neuronal type-specific recombinant gene expression is required for
many potential applications of neuronal gene transfer. One approach is to target gene transfer to a specific
type of neuron. We developed modified Herpes Simplex Virus (HSV-1) particles that contain chimeric
glycoprotein C (gC) – glial cell line-derived neurotrophic factor (GDNF) or brain-derived neurotrophic
factor (BDNF) proteins. HSV-1 vector particles containing either gC – GDNF or gC – BDNF target gene
transfer to nigrostriatal neurons, which contain specific receptors for GDNF or BDNF. A second approach
to achieve neuronal type-specific expression is to use a cell type-specific promoter, and we have used the
tyrosine hydroxylase (TH) promoter to restrict expression to catecholaminergic neurons or a modified
neurofilament heavy gene promoter to restrict expression to neurons, and both of these promoters
support long-term expression from HSV-1 vectors. To both improve nigrostriatal-neuron specific
expression, and to establish that targeted gene transfer can be followed by long-term expression, we
performed targeted gene transfer with vectors that support long-term, neuronal-specific expression.
Results: Helper virus-free HSV-1 vector packaging was performed using either gC – GDNF or gC –
BDNF and vectors that contain either the TH promoter or the modified neurofilament heavy gene
promoter. Vector stocks were injected into the midbrain proximal to the substantia nigra, and the rats
were sacrificed at either 4 days or 1 month after gene transfer. Immunofluorescent costaining was
performed to detect both recombinant gene products and nigrostriatal neurons. The combination of
targeted gene transfer with neuronal-specific promoters improved nigrostriatal neuron-specific
expression (83 to 93%) compared to either approach alone, and supported long-term (1 month)
expression at levels similar to those observed using untargeted gene transfer.
Conclusion: Targeted gene transfer can be used in combination with neuronal-specific promoters to
achieve a high level of nigrostriatal neuron-specific expression. Targeted gene transfer can be followed by
long-term expression. Nigrostriatal neuron-specific expression may be useful for specific gene therapy
approaches to Parkinson's disease or for genetic analyses of nigrostriatal neuron physiology.
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Background
Gene transfer directly into neurons, using specific virus
vectors, has potential for developing gene therapy treat-
ments for specific neurological diseases and for studying
neuronal physiology. However, due to the heterogeneous
cellular composition of the brain, neuronal subtype-spe-
cific expression is required for many potential uses of neu-
ral gene transfer. The two predominate approaches are to
target gene transfer to a specific cell type using a modified
vector particle or to use a cell type-specific promoter to
control expression [1-6]. A higher level of cell type-specific
expression may be achieved by using these two comple-
mentary approaches together.
Helper virus-free HSV-1 vectors are attractive; they effi-
ciently transduce neurons, have a large capacity, and cause
minimal cytotoxicity [7-9]. The HSV-1 particle is com-
posed of four components: i) The ~152 kb double
stranded DNA genome is contained within ii) an icosahe-
dral protein capsid, that is surrounded by iii) the tegu-
ment, a layer of proteins, and enclosed within iv) the
envelope, a lipid bilayer containing 10 virally-encoded
glycoproteins [10]. HSV-1 infection occurrs in two stages
[11]. The initial binding to the cell surface is mediated by
specific domains on glycoprotein C (gC) and gB that rep-
resent binding sites for glycosaminoglycans, principally
heparin sulfate, present on cell surface proteoglycans [12-
15]. Entry requires the subsequent binding of gD to a spe-
cific receptor. gD receptors include nectin-1 or nectin-2 of
the immunoglobulin superfamily; the herpesvirus entry
mediator (HVEM), which is a member of the tumor necro-
sis receptor family; and sites in heparin sulfate produced
by specific isoforms of 3-O-sulfotransferases [11]. Entry
occurs by fusion of the cell membrane and the viral enve-
lope, and requires gB, gD, gH, and gL.
Targeted gene transfer with HSV-1 vectors was achieved by
modifying gC to remove the heparin binding domain,
and addition a binding site for a specific cell surface pro-
tein to either gC or gD. The initial study [16] reported a
recombinant virus containing a chimeric gC – erythropoi-
etin (EPO) that supported enhanced binding to cells that
contained EPO receptors. Analogous designs used gD –
IL13, or gD – urokinase plaminogen activator, or gD – sin-
gle-chain anti-EGF receptor antibody chimeric proteins to
target infection to tumor cells containing the cognate
receptor [17-19]. Another study [20] used a HSV-1 plas-
mid (amplicon) vector expressing gC – His tag, and pack-
aging with a helper virus deleted in gC; this strategy
targeted infection to a cell line containing a pseudo-His-
tag receptor. All of these reports [16-20] used specific
HSV-1 viruses that grow productively and kill infected
cells, confounding potential gene transfer studies.
We reported targeted gene transfer to a specific type of
neuron in the brain [21]. Helper virus-free packaging was
performed using pHSVlac [22] and either gC – glial cell
line-derived neurotrophic factor (GDNF) or gC – brain-
derived neurotrophic factor (BDNF) chimeric protein.
Delivery of either vector stock into the midbrain sup-
ported 2.2 to 5.0-fold targeted gene transfer to nigrostri-
atal neurons [21], which contain both the GDNF receptor
α-1 (GFRα-1 [23,24]) and the high-affinity BDNF recep-
tor, TrkB[25,26]. Specifically, 75 to 80% of the transduced
cells were nigrostriatal neurons, compared to 15–30%
using untargeted gene transfer; and for the untargeted
expression, 5 to 10% was in each of GABAergic neurons
and glial fibrillary acidic protein-containing cells [21]. At
times shortly after gene transfer, the HSV-1 immediate
early (IE) 4/5 promoter in pHSVlac [22] supports expres-
sion in most cell types, which enabled an accurate assess-
ment of the types of transduced cells. However, pHSVlac
does not support significant levels of long-term expres-
sion in most neural cell types, and these rats were sacri-
ficed at 4 days after gene transfer.
Specific promoters support long-term expression in neu-
rons, or specific types of neurons, from HSV-1 vectors. To
obtain long-term, neuronal-specific expression, we con-
structed a chimeric promoter containing a neurofilament
heavy gene (NF-H) promoter, an upstream enhancer from
the tyrosine hydroxylase (TH) promoter, and a β-globin
insulator (INS-TH-NFH promoter [5]). Vectors containing
the INS-TH-NFH promoter supported expression for 7, 8,
or 14 months [27-29], and at 6 months, ~11,400 striatal
neurons contained recombinant gene products (with 3
injection sites for gene transfer, [27]). Alternatively, vec-
tors containing the TH promoter supported expression for
at least 2 months in midbrain dopaminergic neurons,
including nigrostriatal neurons (helper virus system
[6,30]; helper virus-free system [31]). Of note, 40 to 60%
of the transduced cells were nigrostriatal neurons [6,31],
compared to 5% using pHSVlac [6]. Targeted gene transfer
or use of the TH promoter each supported only partial
nigrostriatal-specific expression, raising the possibility
that further improvements in nigrostriatal-specific expres-
sion might be obtained by combining these complemen-
tary approaches.
Both to improve nigrostriatal neuron-specific expression,
and to establish that targeted gene transfer can be fol-
lowed by long-term expression, we performed targeted
gene transfer using vectors that contain either the TH or
INS-TH-NFH promoter. The combination of targeted gene
transfer and a neuronal-specific promoter improved
nigrostriatal neuron-specific expression to 83 to 93%. Of
note, the levels of expression at 1 month were similar to
those previously observed using untargeted gene transfer
with each promoter.BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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Results
Vectors containing neuronal-specific promoters can be 
packaged using either gC – GDNF or gC – BDNF
The combination of targeted gene transfer with vectors
that contain neuronal-specific promoters may support a
higher level of nigrostriatal neuron-specific expression
than either approach alone. Because gC – GDNF or gC –
BDNF supported a similar level of targeted gene transfer to
nigrostriatal neurons (75 to 80%) at 4 days after gene
transfer [21], we decided to examine each construct. To
explore the potential for targeted gene transfer to be fol-
lowed by long-term expression, we decided to test two
promoters that can support long-term expression in
nigrostriatal neurons, the TH or INS-TH-NFH promoters
[5,6]. We arbitrarily chose the combinations of gC –
BDNF targeting with a vector containing the TH promoter
(pTHlac/gC – bdnf), or gC – GDNF targeting with a vector
containing the INS-TH-NFH promoter (pINS-TH-NFHlac/
gC – gdnf).
We quantified the additional nigrostriatal neuron-specific
expression supported by the combination of targeted gene
transfer using a neuronal-specific promoter by compari-
son to a pHSVlac-type vector. At times shortly after gene
transfer, pHSVlac-type vectors, which contain the HSV-1
IE 4/5 promoter, support expression in most types of neu-
ral cells. To enable comparisons within the same rats to
vectors that express β-galactosidase (β-gal), we used
pHSVpkcΔGG. pHSVpkcΔGG expresses a flag-tagged cata-
lytic domain of protein kinase C (PKC), and contains a
point mutation that abolishes protein kinase activity [32].
These vectors were packaged into HSV-1 particles for tar-
geted gene transfer (Figure 1). The titers obtained for pTH-
lac/gC – bdnf or pINS-TH-NFHlac/gC – gdnf were similar
to the titers obtained for pHSVpkcΔGG/gC – bdnf or
pHSVpkcΔGG/gC – gdnf (titers in methods), or the titers
previously reported for either pHSVlac/gC – bdnf or pHS-
Vlac/gC – gdnf [21]. We previously showed that gC –
GDNF or gC – BDNF are each incorporated into HSV-1
virus particles [21], and we did not perform analogous
Western blot assays in this study. For clarity of presenta-
tion, we first present results on the cell type specificity of
expression supported by pTHlac/gC – bdnf, followed by
the cell type specificity observed using pINS-TH-NFHlac/
gC – gdnf, and then the data on long-term expression.
In the rat brain, pTHlac/gC – bdnf supported higher levels 
of nigrostriatal neuron-specific expression than 
pHSVpkcΔGG/gC – bdnf
Due to the small extent of the substantia nigra pars com-
pacta (SNc) in the dorsal-ventral dimension, and the het-
erogeneous cellular composition of the midbrain,
injections of HSV-1 vectors into the midbrain near the
substantia nigra typically support gene transfer to differ-
ent populations of cells in different rats, complicating
comparisons between rats. To control for the variability in
injection sites between rats, and to quantify the additional
nigrostriatal neuron-specific expression supported by the
TH promoter after targeted gene transfer, we co-injected
mixtures of equal titers of pTHlac/gC – bdnf and pHSVp-
kcΔGG/gC – bdnf (see methods for titers and injection
conditions). The rats were sacrificed at either 4 days or 1
month after gene transfer, the brains were sectioned, and
alternating sections were costained for either β-gal-immu-
noreactivity (IR) and TH-IR, or flag-IR (PkcΔGG contains
the flag tag) and TH-IR. Nigrostriatal neurons contain TH
[33], enabling identification using an anti-TH antibody.
At 4 days after gene transfer, low power photomicro-
graphs showed that most of the β-gal-IR cells were located
in a narrow band that contained TH-IR neurons in the SNc
(Figure 2A–C; pTHlac/gC – bdnf expresses β-gal), and a
few β-gal-IR cells were located ventral to the TH-IR cells.
High power views showed that the clear majority of the β-
gal-IR cells also contained TH-IR (Figure 2D–F). In con-
trast, while many of the flag-IR cells were located within
the band of TH-IR cells, more of the flag-IR cells were
located either dorsal or ventral to the TH-IR cells (Figure
2G–I; pHSVpkcΔGG/gC – bdnf expresses PkcΔGG, which
contains the flag-tag). High power views showed some
that flag-IR cells contained TH-IR, and some flag-IR cells
lacked TH-IR (Figure 2J–L). Cell counts from 4 rats (Table
1) showed that an average of 84 ± 1% (mean ± sem) of the
β-gal-IR cells also contained TH-IR, but only 70 ± 2% of
the flag-IR cells also contained TH-IR.
At 1 month after gene transfer, low power photomicro-
graphs showed that almost all of the β-gal-IR cells were
located within the area of TH-IR neurons in the SNc (Fig-
ure 3A–C), and high power views showed that these β-gal-
IR cells also contained TH-IR (Figure 3D–F). In contrast,
although numerous flag-IR cells were located within the
band of TH-IR cells, many flag-IR cells were located either
dorsal or ventral to the TH-IR cells (Figure 3G–I), similar
to the results from rats sacrificed at 4 days. High power
views showed that some flag-IR cells contained TH-IR,
and some flag-IR cells lacked TH-IR (Figure 3J–L). Cell
counts from 2 rats (Table 2; there were technical issues
with perfusing 1 rat) showed that an average of 93 ± 1%
of the β-gal-IR cells also contained TH-IR, but only 72 ±
3% of the flag-IR cells also contained TH-IR. Statistical
analysis showed that significantly more β-gal-IR than flag-
IR cells contained TH-IR (condition p < 0.0001, sacrifice
time p < 0.05, 2-way ANOVA).
We previously showed that pretreatment of a pHSVlac/gC
– bdnf stock with an anti-BDNF antibody reduced tar-
geted gene transfer to nigrostriatal neurons to ~16%, a
level similar to that obtained using untargeted gene trans-BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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fer [21]. Analogous studies were not repeated using the
current vector stocks.
pINS-TH-NFHlac/gC – gdnf supported higher levels of 
nigrostriatal neuron-specific expression than 
pHSVpkcΔGG/gC – gdnf
We co-injected mixtures of equal titers of pINS-TH-NFH-
lac/gC – gdnf and pHSVpkcΔGG/gC – gdnf into the mid-
brain proximal to the SNc, and the rats were sacrificed at
either 4 days or 1 month after gene transfer. At 4 days after
gene transfer, low power photomicrographs showed that
most of the β-gal-IR cells were located within the area of
TH-IR neurons (Figure 4A–C), and low numbers of β-gal-
IR cells were located ventral to the TH-IR cells. High power
views showed that most of these β-gal-IR cells also con-
tained TH-IR (Figure 4D–F). In contrast, many of the flag-
Schematic diagrams of (A) the gC – BDNF construct, or (B) helper virus-free packaging for targeted gene transfer Figure 1
Schematic diagrams of (A) the gC – BDNF construct, or (B) helper virus-free packaging for targeted gene transfer. A. gC – 
BDNF contains the gC promoter, a BDNF cDNA (preproBDNF, aa 1–247), a spacer of 5 aa, and a deletion of gC containing aa 
153 to the C-terminus (aa 511) [21]. Expression of gC – BDNF will be regulated similar to the wt gC gene, as this construct 
retained the gC promoter and polyadenylation site. BDNF, a secreted protein, contains a signal sequence [46] to support 
proper posttranslational processing, and the gC deletion retains the transmembrane domain to support insertion into the 
envelope of HSV-1 particles. B. Helper virus-free packaging [7, 50] was performed using either pTHlac or pINS-TH-NFHlac 
and either gC – BDNF or gC – GDNF. A HSV-1 vector and a HSV-1 cosmid set that contained a modified gC construct and 
lacks an a sequence (contains the packaging site) were cotransfected into 2-2 cells [51]. The resulting HSV-1 vector particles 
should contain the vector, modified gC, and all the other HSV-1 envelope glycoproteins. Thus, these vector particles are 
designed to enable initial binding to either BDNF or GDNF receptors on the surface of cells, followed by entry using the same 
mechanism as used by wt HSV-1 particles [11].BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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IR cells were located within the band of TH-IR cells, and
many of the flag-IR cells were located ventral to the TH-IR
cells (Figure 4G–I). Consistent with the low power views,
high power views showed that some flag-IR cells con-
tained TH-IR, and other flag-IR cells lacked TH-IR (Figure
4J–L). Cell counts from 3 rats (Table 3) showed that an
average of 83 ± 2% of the β-gal-IR cells also contained TH-
IR, but only 68 ± 2% of the flag-IR cells also contained TH-
IR.
At 1 month after gene transfer, low power photomicro-
graphs showed that the area of β-gal-IR cells closely fol-
lowed the area of TH-IR neurons in the SNc (Figure
5A–C), and high power views showed that these β-gal-IR
cells also contained TH-IR (Figure 5D–F). In contrast,
many flag-IR cells were located within the band of TH-IR
cells, and some flag-IR cells were located either dorsal or
ventral to the TH-IR cells (Figure 5G–I). High power views
showed flag-IR cells that either contained or lacked TH-IR
(Figure 5J–L). Cell counts from 3 rats (Table 4) showed
that an average of 92 ± 0% of the β-gal-IR cells also con-
tained TH-IR, but only 69 ± 5% of the flag-IR cells also
contained TH-IR. Statistical analysis showed that signifi-
cantly more β-gal-IR than flag-IR cells contained TH-IR
(condition p < 0.001, sacrifice time p > 0.05, 2-way
ANOVA).
Following targeted gene transfer, pTHlac or pINS-TH-
NFHlac supported long-term expression
The cell counts in Tables 1, 2, 3, 4 were used to calculate
the total numbers of β-gal-IR cells supported by each vec-
tor, at either 4 days or 1 month after gene transfer. The
results (Table 5) showed that the INS-TH-NFH or TH pro-
moter each supported 37% of the number of cells at 1
month compared to 4 days. This 37% stability of long-
term expression is similar the stabilities of expression
observed following standard, untargeted gene transfer
using either pTHlac [6,31] or pINS-TH-NFHlac [5]. Sur-
prisingly, the IE 4/5 promoter supported 23 to 28% stabil-
ity of expression in nigrostriatal neurons. In contrast,
using untargeted gene transfer, pHSVlac supports ≤ 1%
stability of expression at 1 month in the striatum, hippoc-
ampus, or specific neocortical areas [7,34,35]. Congru-
ently, transgenic mice that contain specific HSV-1 IE
promoters controlling a reporter gene showed that spe-
cific IE promoters support expression in only a few spe-
cific types of neurons [36-38]. Thus, the IE 4/5 promoter
in pHSVlac-type vectors appears to selectively support
higher levels of long-term expression in nigrostriatal neu-
rons than in most other types of neurons, including those
in the midbrain, striatum, or hippocampus [7,34,35].
Discussion
The combination of targeted gene transfer with a vector
that contains a neuronal-specific promoter improved
nigrostriatal neuron-specific expression, compared to
either approach alone. Untargeted gene transfer with pHS-
Vlac-type vectors supported 5 to 30% nigrostriatal neu-
ron-specific expression [6,21]; pHSVlac-type vectors
contain the HSV-1 IE 4/5 promoter that is active in multi-
ple types of neural cells at times shortly after gene transfer.
pTHlac, with standard untargeted gene transfer, sup-
ported 40 to 60% nigrostriatal neuron-specific expression
[6,31]. Targeted gene transfer with pHSVlac-type vectors
supported 68 to 80% nigrostriatal neuron-specific expres-
sion (this study and [21]). Targeted gene transfer with vec-
tors containing the TH or INS-TH-NFH promoter
supported 83 or 84% nigrostriatal neuron-specific expres-
sion at 4 days after gene transfer, and 92 or 93% nigrostri-
atal neuron-specific expression at 1 month after gene
transfer. The ~10% increase in nigrostriatal neuron-spe-
cific expression between 4 days and 1 month after gene
transfer may be due to a higher level of inappropriate
expression from the neuronal-specific promoter at 4 days,
before chromatin structure on the vectors has reached
steady levels.
Table 1: The numbers of β-gal or PkcΔGG positive cells that contained TH-IR, in rats sacrificed at 4 days after co-injection of pTHlac/
gC – bdnf and pHSVpkcΔGG/gC – bdnf into the midbrain
Numbers of positive cells % Numbers of positive cells %
Rat β-gal-IR TH-IR Costained Flag-IR TH-IR Costained
1 347 287 83 328 232 71
2 322 278 86 205 134 66
3 340 274 81 470 354 75
4 418 358 86 310 212 68
Average 84 ± 1 70 ± 2
A mixture of equal IVP/ml of pTHlac/gC – bdnf and pHSVpkcΔGG/gC – bdnf (for titers and injection conditions, see methods) was injected into the 
midbrain proximal to the substantia nigra. The rats were perfused at 4 days after gene transfer, the brains were sectioned, and alternating sections 
were costained for either β-gal-IR or flag-IR and TH-IR. Sufficient sections were examined to count at least 200 cells that contained either β-gal-IR 
or flag-IR in each rat. In the sections that were examined, all of the β-gal-IR or flag-IR cells were scored for containing or lacking TH-IR. For the 
average % costaining, the means ± sems are shown.BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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Costaining for nigrostriatal neuron-specific recombinant gene expression in rats sacrificed at 4 days after co-injection of pTH- lac/gC – bdnf and pHSVpkcΔGG/gC – bdnf into the midbrain Figure 2
Costaining for nigrostriatal neuron-specific recombinant gene expression in rats sacrificed at 4 days after co-injection of pTH-
lac/gC – bdnf and pHSVpkcΔGG/gC – bdnf into the midbrain. Alternating sections were costained using either rabbit anti-β-gal 
and mouse anti-TH or mouse anti-flag (detects PkcΔGG) and rabbit anti-TH, and these antibodies were visualized using rhod-
amine- or fluorescein-conjugated secondary antibodies. A-F. pTHlac/gC – bdnf supported expression of β-gal in nigrostriatal 
neurons: Low power (A-C); β-gal-IR (A), TH-IR (B), and merge (C). High power (D-F); β-gal-IR (D), TH-IR (E), and merge (F). 
Arrows indicate examples of costained cells. G-I. pHSVpkcΔGG/gC – bdnf supported expression of β-gal in nigrostriatal neu-
rons, with some expression in cells that lacked TH-IR: Low power (G-I); flag-IR (G), TH-IR (H), and merge (I). High power (J-
L); β-gal-IR (D), TH-IR (E), and merge (F). Arrowheads indicate examples of flag-IR only. Scale bars: (A-C and G-I) 100 μm, (D-
F and J-L) 30 μm.BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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Targeted gene transfer with each of the neuronal-specific
promoters supported similar levels of nigrostriatal neu-
ron-specific expression, although the TH promoter is spe-
cific for nigrostriatal neurons while the INS-TH-NFH
promoter is active in most types of neurons. Using tar-
geted gene transfer with pHSVlac-type vectors, we showed
that ~5% of the gene transfer was to glutamic acid decar-
boxylase (GAD)-IR neurons and [21], and GABAergic
neurons in the substantia nigra pars reticulata are adjacent
to the SNc. Also, using targeted gene transfer with pHSV-
Costaining for nigrostriatal neuron-specific recombinant gene expression in rats sacrificed at 1 month after co-injection of  pTHlac/gC – bdnf and pHSVpkcΔGG/gC – bdnf into the midbrain Figure 3
Costaining for nigrostriatal neuron-specific recombinant gene expression in rats sacrificed at 1 month after co-injection of 
pTHlac/gC – bdnf and pHSVpkcΔGG/gC – bdnf into the midbrain. Alternating sections were costained using either anti-β-gal 
and anti-TH, or anti-flag (detects PkcΔGG) and anti-TH. A-F. pTHlac/gC – bdnf supported expression of β-gal in nigrostriatal 
neurons: Low power (A-C); β-gal-IR (A), TH-IR (B), and merge (C). High power (D-F); β-gal-IR (D), TH-IR (E), and merge (F). 
Arrows indicate examples of costained cells. G-I. pHSVpkcΔGG/gC – bdnf supported expression of β-gal in nigrostriatal neu-
rons, with some expression in cells that lacked TH-IR: Low power (G-I); flag-IR (G), TH-IR (H), and merge (I). High power (J-
L); β-gal-IR (D), TH-IR (E), and merge (F). Arrowheads indicate examples of flag-IR only. Scale bars: (A-C and G-I) 100 μm, (D-
F and J-L) 30 μm.BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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lac-type vectors, we showed that 5 to 12% of the gene
transfer was to glial fibrillary acidic protein (GFAP)-IR
cells [21], and we did not examine gene transfer to other
types of glia. Thus, inappropriate gene transfer to glla
appears to account for more of the inappropriate gene
transfer than gene transfer to other types of neurons, and
both the TH and INS-TH-NFH promoters are neuronal-
specific promoters that will reduce the inappropriate
expression in glia.
Targeted gene transfer with either gC – GNDF or gC –
BDNF was not complete, and some gene transfer to inap-
propriate cell types was observed (this study and [21]).
The fragment of gC in either gC – GDNF or gC – BDNF
lacks the heparin sulfate binding domain [14,39]; but the
vector particles still contain gB, which contains a heparin
sulfate binding domain [15,40]. In the context of HSV-1
viruses, deletion of either the gC or gB heparin sulfate
binding domain reduced binding to fibroblast cells ~65%
or ~20%, respectively, and deletion of both domains was
approximately additive, reducing binding ~80% [15].
Thus, use of both a gB lacking a heparin sulfate binding
domain (gBpK- [15]) and a chimeric gC might improve
targeted gene transfer to nigrostriatal neurons.
Using pHSVlac-type vectors, gC – GNDF or gC – BDNF
appear to support similar levels of targeted gene transfer
(this study and [21]); although over 20 rats have been
analyzed, these are comparisons between different rats
that do not control for variability in injection sites
between rats. The untargeted gene transfer supported by
the wt gB in these vector particles may be a larger variable
than any differences in targeting efficiency between gC –
GNDF or gC – BDNF. Of note, GDNF is more effective
than BDNF in protecting nigrostriatal neurons in the 6-
OHDA rat model of Parkinson's disease [29]. However,
neuroprotection requires intracellular signaling, whereas
targeted gene transfer requires only binding of the vector
particle to the appropriate receptor on the cell surface. As
nigrostriatal neurons contain high levels of both the
GDNF receptor α-1 (GFRα-1 [23,24]) and the high-affin-
ity BDNF receptor, TrkB [25,26], gC – GNDF or gC –
BDNF may support similar efficiencies of targeted gene
transfer to nigrostriatal neurons.
Following targeted gene transfer, the TH or INS-TH-NFH
promoters supported levels of long-term expression that
were similar to those observed following untargeted,
standard gene transfer. gC – GNDF or gC – BDNF likely
alter only the initial binding to cells, After the initial bind-
ing to cells, entry occurs by fusion of the cell membrane
and the viral envelope, and requires gB, gD, gH, and gL.
Thus, using either targeted gene transfer or standard gene
transfer, entry, vector particle uncoating, and gene expres-
sion are likely to occur by similar pathways.
Conclusion
Our results establish that following targeted gene transfer,
specific promoters can support long-term expression from
HSV-1 vectors. Targeted gene transfer to nigrostriatal neu-
rons, followed by long-term expression, may be useful for
specific gene therapy treatments or physiological studies.
In relation to Parkinson's disease, clinical trials with
recombinant GDNF protein were halted due to side effects
Table 2: The numbers of β-gal or PkcΔGG positive cells that contained TH-IR, in rats sacrificed at 1 month after co-injection of pTHlac/
gC – bdnf and pHSVpkcΔGG/gC – bdnf into the midbrain
Numbers of positive cells % Numbers of positive cells %
Rat β-gal-IR TH-IR Costained Flag-IR TH-IR Costained
1 201 184 92 129 89 69
2 183 171 93 110 82 75
Average 93 ± 1 72 ± 3
This experiment was performed as in Table 1, except the rats were perfused at 1 month after gene transfer.
Table 3: The numbers of β-gal or PkcΔGG positive cells that contained TH-IR, in rats sacrificed at 4 days after co-injection of pINS-TH-
NFHlac/gC – gdnf and pHSVpkcΔGG/gC – gdnf into the midbrain
Numbers of positive cells % Numbers of positive cells %
Rat β-gal-IR TH-IR Costained Flag-IR TH-IR Costained
1 471 378 80 535 344 64
2 758 625 83 652 467 72
3 444 384 87 474 316 67
Average 83 ± 2 68 ± 2
This experiment was performed as in Table 1, except a mixture of equal titers of pINS-TH-NFHlac/gC – gdnf and pHSVpkcΔGG/gC – gdnf was 
injected into the midbrain.BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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[41-43], suggesting that more restricted expression of
GDNF is desirable. In relation to studies on neuronal
physiology, transgenic mice that use the TH promoter to
control recombinant gene expression will alter expression
in most catecholaminergic neurons, whereas the
approach described here can support a selective analysis
of nigrostriatal neuron physiology. More generally, tar-
geted gene transfer followed by long-term expression may
have specific clinical or basic neuroscience applications in
brain areas that contain a complex mixture of different
Costaining for nigrostriatal neuron-specific recombinant gene expression in rats sacrificed at 4 days after co-injection of pINS- TH-NFHlac/gC – gdnf and pHSVpkcΔGG/gC – gdnf into the midbrain Figure 4
Costaining for nigrostriatal neuron-specific recombinant gene expression in rats sacrificed at 4 days after co-injection of pINS-
TH-NFHlac/gC – gdnf and pHSVpkcΔGG/gC – gdnf into the midbrain. Alternating sections were costained using either anti-β-
gal and anti-TH, or anti-flag and anti-TH. A-F. pINS-TH-NFHlac/gC – gdnf supported expression of β-gal in nigrostriatal neu-
rons: Low power (A-C); β-gal-IR (A), TH-IR (B), and merge (C). High power (D-F); β-gal-IR (D), TH-IR (E), and merge (F). 
Arrows indicate examples of costained cells. G-I. pHSVpkcΔGG/gC – gdnf supported expression of β-gal in nigrostriatal neu-
rons, with some expression in cells that lacked TH-IR: Low power (G-I); flag-IR (G), TH-IR (H), and merge (I). High power (J-
L); β-gal-IR (D), TH-IR (E), and merge (F). Arrowheads indicate examples of flag-IR only. Scale bars: (A-C) 100 μm, (G-I) 100 
μm, (D-F and J-L) 30 μm.BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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types of neurons, including the midbrain, and possibly
also specific forebrain areas.
Methods
Materials
Dulbecco's modified minimal essential medium, fetal
bovine serum, G418, lipofectamine, and OPTI-MEM I
were obtained from Invitrogen. 5-bromo-4-chloro-3-
Costaining for nigrostriatal neuron-specific recombinant gene expression in rats sacrificed at 1 month after co-injection of  pINS-TH-NFHlac/gC – gdnf and pHSVpkcΔGG/gC – gdnf into the midbrain Figure 5
Costaining for nigrostriatal neuron-specific recombinant gene expression in rats sacrificed at 1 month after co-injection of 
pINS-TH-NFHlac/gC – gdnf and pHSVpkcΔGG/gC – gdnf into the midbrain. Alternating sections were costained using either 
anti-β-gal and anti-TH, or anti-flag and anti-TH. A-F. pINS-TH-NFHlac/gC – gdnf supported expression of β-gal in nigrostriatal 
neurons: Low power (A-C); β-gal-IR (A), TH-IR (B), and merge (C). High power (D-F); β-gal-IR (D), TH-IR (E), and merge (F). 
Arrows indicate examples of costained cells. G-I. pHSVpkcΔGG/gC – gdnf supported expression of β-gal in nigrostriatal neu-
rons, with some expression in cells that lacked TH-IR: Low power (G-I); flag-IR (G), TH-IR (H), and merge (I). High power (J-
L); β-gal-IR (D), TH-IR (E), and merge (F). Scale bars: (A-C and G-I) 100 μm, (D-F and J-L) 30 μmBMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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indoyl-β-D-galactopyranoside (X-Gal) was obtained from
Sigma. Mouse anti-E. coli β-gal and mouse monoclonal
anti-flag were obtained from Sigma, and rabbit anti-TH
was obtained from Chemicon. Rhodamine isothiocy-
anate-conjugated goat anti-mouse immunoglobulin (Ig)
G and fluorescein isothiocyanate-conjugated goat anti-
rabbit IgG were obtained from Jackson ImmunoResearch
Laboratories.
Cosmids and vectors
The HSV-1 genome is represented by cosmid set C (cos6,
cos14, cos28, cos48, cos56, [44]); the a  sequence was
deleted from the two cosmids that contained it (cos6Δa,
cos48Δa [7]). cos56 gC – GNDF and cos56 gC – BNDF
have been described [21]. These chimeric gC (Figure 1)
deleted aa 1–152 of gC, removing the heparin sulfate
binding domain [12-14], required for the initial attach-
ment of HSV-1 particles to the cell surface. This deletion
retained the transmembrane and internal domains to sup-
port insertion of the chimeric proteins into the HSV-1 par-
ticle envelope. A GDNF cDNA or a BDNF cDNA was
inserted inframe at the N-terminus of the gC deletion,
with 5 aa spacer separating the two domains; pre-
proGDNF is 211 aa and mature GDNF is 134 aa [45], or
preproBDNF is 247 aa and mature BDNF is 119 aa [46].
GDNF or BDNF each contain a signal sequence [45,46], to
support posttranslational processing of the chimeric pro-
tein. These constructs retained the gC promoter and poly-
adenylation site, enabling expression to be regulated
similar to wt gC.
HSV-1 vectors that express the Lac Z gene from either a 6.8
kb fragment of the TH promoter (pTHlac [6]) or a modi-
fied neurofilament promoter (pINS-TH-NFHlac [5]) have
been described. The INS-TH-NFH promoter contains a
mouse NF-H promoter (0.6 kb fragment from plasmid
pH-615 [47]), upstream sequences from the rat TH pro-
moter (-0.5 kb to -6.8 kb [48]), and the chicken β-globin
INS (1.2 kb [49]). pHSVpkcΔGG [32] contains the
pkcΔGG gene under the control of the HSV-1 IE 4/5 pro-
moter. PkcΔ is a flag-tagged, catalytic domain of rat PKC
βII, and PkcΔGG contains a point mutation in an evolu-
tionarily conserved lys residue that abolishes PKC enzyme
activity [32].
Cells, vector packaging, and titering
The growth of baby hamster kidney fibroblast (BHK21)
cells [50] and 2-2 cells [51] have been described. Helper
virus-free packaging [7] was performed using a modified
protocol [50] that improves the efficiency. 2-2 cells were
cotransfected with a vector and a HSV-1 cosmid set that
lacked a packaging site (cos6Δa, cos14, cos28, cos48Δa,
and one of two cos56 (containing gC – GNDF or gC –
BNDF)). Vector stocks were purified [52].
Vector stocks were titered by counting the numbers of
positive cells at 1 day after transduction of BHK fibroblast
cells. Vectors that express β-gal were titered by staining
with X-gal, and pHSVpkcΔGG stocks were titered using an
anti-flag antibody [32]. Vector stocks were titered on BHK
cells as the best available assay, as these cells form a mon-
Table 4: The numbers of β-gal or PkcΔGG positive cells that contained TH-IR, in rats sacrificed at 1 month after co-injection of pINS-
TH-NFHlac/gC – gdnf and pHSVpkcΔGG/gC – gdnf into the midbrain
Numbers of positive cells % Numbers of positive cells %
Rat β-gal-IR TH-IR Costained Flag-IR TH-IR Costained
1 240 223 93 156 122 78
2 144 132 92 148 88 60
32 2 8 2 1 0 9 2 8 2 5 6 6 8
Average 92 ± 0 69 ± 5
This experiment was performed as in Table 1, except a mixture of equal titers of pINS-TH-NFHlac/gC – gdnf and pHSVpkcΔGG/gC – gdnf was 
injected into the midbrain, and the rats were perfused at 1 month after gene transfer.
Table 5: pTHlac or pINS-TH-NFHlac support expression for 1 month after targeted gene transfer to nigrostriatal neurons using either 
gC – bdnf or gC – gdnf, respectively
Numbers of positive cells % Long-term expression*
4 days 1 month
Vectors gC β-gal-IR Flag-IR β-gal-IR Flag-IR β-gal Flag
pTHlac & pHSVpkcΔGG gC – bdnf 2,071 ± 602 1,723 ± 284 768 ± 36 478 ± 38 37 28
pINS-TH-NFHlac & pHSVpkcΔGG gC – gdnf 2,230 ± 402 2,214 ± 209 816 ± 121 515 ± 94 37 23
Using pTHlac & pHSVpkcΔGG, 4 rats were analyzed at 4 days, and 2 rats were analyzed at 1 month. Using pINS-TH-NFHlac & pHSVpkcΔGG, 3 
rats were analyzed each time point. The means ± sems are shown.
*% long-term expression = β-gal-IR cells at 1 month/β-gal-IR cells at 4 days × 100.BMC Neuroscience 2008, 9:37 http://www.biomedcentral.com/1471-2202/9/37
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olayer; in contrast, PC12 cells, and most neuronal cell
lines, do not form a monolayer. Thus, the titers obtained
on BHK cells are higher than the titers obtained on PC12
cells [5,53]. Expression from the TH or INS-TH-NFH pro-
moter in fibroblast cells is ectopic expression, and this
inappropriate expression declined rapidly at longer times
after gene transfer (not shown). wt HSV-1 was not
detected in these vector stocks (<10 plaque forming units
(pfu)/ml).
We previously used PCR assays to quantify the vector
genomes (VG)/ml of vectors packaged using either gC –
GNDF or gC – BNDF [21]. The VG/ml of these stocks were
similar to those obtained using wt gC; the ratio of VG/IVP
ranged from 1 to 45, and wt gC supports a ratio of ~10. We
did not repeat the assay for VG/ml, because the present
study applied the same packaging conditions to different
vectors.
Gene transfer experiments in the brain
These studies were approved by the West Roxbury VA Hos-
pital IACUC. Male Sprague Dawley rats (175–200 gm)
were used for these experiments. Appropriate volumes of
pTHlac/gC – bdnf and pHSVpkcΔGG/gC – bdnf were
mixed together to yield a titer of 1.8 × 106 IVP/ml for each
vector, and appropriate volumes of pINS-TH-NFHlac/gC
– gdnf and pHSVpkcΔGG/gC – gdnf were mixed together
to yield a titer of 5.0 × 105 IVP/ml for each vector. Each
mixture of vector stocks was delivered by stereotactic
injection (2 sites, 3 μl/site) into the midbrain proximal to
the substantia nigra of the right hemisphere (anterior-pos-
terior (AP) -5.5, medial-lateral (ML) -1.9, dorsal-ventral
(DV) -7.1; AP -5.5, ML -2.3, DV -6.8) [21]. AP is relative to
bregma, ML is relative to the sagittal suture, and DV is rel-
ative to the bregma-lambda plane [54]. Injections used a
micropump (model 100, KD Scientific); the 3 μl innocu-
lum was injected over ~5 minutes, the needle was main-
tained in place for an additional 5 minutes, and then
slowly withdrawn over ~5 minutes. Rats were perfused,
brains were sectioned, and immunofluorescent costaining
was performed, as described [5]. Alternating sections were
costained with either mouse anti-β-gal (1:200 dilution) or
mouse anti-flag (detects PkcΔGG, 1:1,000 dilution) and
rabbit anti-TH (1:1,000 dilution). Primary antibodies
were visualized using rhodamine isothiocyanate-conju-
gated goat anti-mouse IgG and fluorescein isothiocy-
anate-conjugated goat anti-rabbit IgG.
Cell counts
Twenty-five μm coronal sections that contained the mid-
brain were prepared, and recombinant gene products
were detected in ~20 of these sections. Alternating sec-
tions were analyzed for costaining of either β-gal-IR or
PkcΔGG (flag-IR) and TH-IR. Photomicrographs were
taken under 60× magnification using a video camera. The
positive cells (β-gal-IR or flag-IR) in each section were
scored for costaining with TH-IR, and all the positive cells
in each section were scored. Each section was counted at
least two times, on different days, and the two values dif-
fered by <10% for each section.
Statistical analyses
Statistical comparisons were performed using ANOVAs
(Sigmastat).
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